Company profile
Bioasis Technologies Inc.
OTC: BIOAF · Healthcare · Biotechnology
#1104 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ —GM —SS 30
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ operating margin, revenue growth (YoY)
Methodology →Revenue TTM
$204.0k
Rev growth YoY (TTM)
+579.2%
Net income (FY)
-$2.4M
Employees
4
as of 2026-08-30
Market cap
$7.9k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$30.1k37.7k CAD2022
Net income-$2.4M-3.0M CAD2022
Operating income-$3.8M-4.8M CAD2022
Total assets$1.8M2.3M CAD2022
Liabilities$3.3M4.2M CAD2022
Equity-$1.5M-1.9M CAD2022
Revenue trend
FY2017 – FY2022 · USD
FY17
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bioasis Technologies Inc.’s revenue?
Bioasis Technologies Inc. booked $30.1k in FY2022 revenue, contracting 99% year over year — among the slowest-growing Healthcare companies we track, at a -7846.5% net margin.
Peers · Healthcare
CuraScientific Corp——Impact BioMedical Inc.32DenVVeno Medical Corporation40DUMC, Inc.——Talphera, Inc.47DProteonomix, Inc.——Neighbors
New Haven →Key facts
CEODeborah Ann Rathjen
SectorHealthcare
IndustryBiotechnology
HeadquartersNew Haven, CT
ExchangeOTC: BIOAF
Employees4
IPO date2010-12-31
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.